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HbFSickle cell anaemia (SCA) results from a single mutation in the β globin gene. It is seldom symptomatic in
the ﬁrst semester of life. We analysed the expression pattern of 9 adhesion molecules on red blood cells,
in a cohort of 54 SCA and 17 non-SCA very young infants of comparable age (median 144 days, 81–196).
Haemoglobin F (HbF) level was unsurprisingly elevated in SCA infants (41.2% ± 11.2) and 2–4 fold higher
than in non-SCA infants, yet SCA infants presented signiﬁcantly decreased Hb level and increased
reticulocytosis. Cytometry analysis evidenced a speciﬁc expression proﬁle on reticulocytes of SCA infants,
with notably an increased expression of the adhesion molecules Lu/BCAM, ICAM-4 and LFA-3, both in
percentage of positive cells and in surface density. No signiﬁcant difference was found on mature red
cells. Our ﬁndings demonstrate the very early onset of reticulocyte membranemodiﬁcations in SCA asymptom-
atic infants and allow an insight into the ﬁrst pathological changes with the release of stress reticulocytes
expressing a distinctive proﬁle of adhesion molecules.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Sickle cell anaemia (SCA) is caused by a mutation in the β globin
gene. Sickle haemoglobin (HbS) polymerises when deoxygenated,
resulting in red cell membrane rigidity and surface protein modiﬁca-
tions that subsequently contribute to vaso-occlusion. SCA is seldom
symptomatic in the ﬁrst six months of life. One main explanation lies
in the sustained level of foetal haemoglobin (HbF) and F cells during
this period (Maier-Redelsperger et al., 1994) preventing HbS polymeri-
sation (Nagel et al., 1979). However, infra clinical vaso occlusion,
particularly in the spleen, occurs at a very early age (Rogers et al.,Sickle Cell Disease, Pediatric
s, APHP, Paris, France.
usse).
. This is an open access article under2011) and the absolute reticulocyte count is already elevated in the
ﬁrst semester of life, arguing for the very early onset of haemolysis
despite high HbF levels (Meier et al., 2013, 2014). Furthermore, in-
creased evidence supports that HbF elevation duringhydroxycarbamide
therapy is insufﬁcient to explain the drug's beneﬁcial effect (Segel et al.,
2011). In fact, it is now considered that abnormal red blood cell (RBC)
adhesiveness in SCA through activation, sustained or increased ex-
pression of adhesion molecules is pivotal in the genesis of vaso
occlusive crisis, the hallmark of SCA (Hebbel et al., 1980). In this
study, we analysed the expression pattern of 9 adhesion molecules
on both reticulocytes and mature RBCs in SCA and non-SCA very
young infants. These markers are known surface molecules, which
allow characterisation of erythroid maturation and/or which are adhe-
sion molecules demonstrated to play an important pathophysiological
role (Cartron and Elion, 2008). Our objectives were to gain insight
into very early pathophysiology by evidencing distinct proﬁles speciﬁ-
cally attributable to SCA.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Patients
Infants diagnosed with SS or S beta° genotypes following neonatal
screening were enrolled in a multi-centre prospective study on prog-
nostic factors in SCA (ClinicalTrials.gov: NCT01207037) between
September 2010 and March 2013. The institutional review boards of
all participating centres approved the study. Written informed consent
in accordance with the Declaration of Helsinki was obtained from all
parents. Blood sampling was performed at enrolment (3–6 months) at
steady state, in asymptomatic infants. In parallel, blood samples from
infants with no haemoglobinopathy (non-SCA-infants) were collected.
For each patient complete blood counts, erythrocyte indices were de-
termined using an Advia 120 Hematology System (SIEMENS, Germany).
HbF was quantiﬁed by high performance ion-exchange liquid
chromatography (HPLC) procedure (BioRad Laboratories, California,
USA).
Samples were stored at−196 °C as previously described (Cartron
and Elion, 2008) at the Centre National de Référence pour les Groupes
Sanguins, Paris, for secondary ﬂow cytometry analysis.
2.2. Flow Cytometry
Flow cytometry analysis was performed using murine monoclo-
nal antibodies against the adhesion molecules CD36, CD44, CD47,
CD49d, CD58, CD99, CD147, CD239 and CD242. A BD FACScanto II
ﬂow cytometer with HTS (Becton-Dickinson) and FACSDiva software
(v6.1.3) were used for acquisition and analysis. The percentage of
RBCs expressing eachmarker and the correspondingmeanﬂuorescence
intensity (MFI)were determined under the same conditions for all sam-
ples. The percentage of reticulocytes was determined using thiazole
orange dye (Retic-CountTM, Becton-Dickinson, San Jose, CA, USA) accord-
ing to the manufacturer instructions. A total of 10,000 events was
analysed for each patient and each molecule.
2.3. Statistical Analysis
Results are presented as means or medians ± SD. Statistical analysis
was performedwith GraphPad Prism 6 (GraphPad Software, La Jolla, CA,
USA) using Mann–Whitney test. A difference between two groups was
considered statistically signiﬁcant when P b 0.05.
3. Results
3.1. Asymptomatic SCA Infants Show Early Haemolytic Anaemia Despite
Sustained HbF Level (Table 1)
Fifty-four SCA infants were analysed and compared to 17 non-SCA
infants. Median age in the two groups was not statistically different
(144 days, range 81–196 versus 128, range 68–621, P = 0.84) so that
no difference in subsequent results would be attributable to this age pa-
rameter. Of note and as expected, none of the SCA infants had clinical
symptoms related to the disease.
Mean HbF level in SCA infants was 41.2% (±11.2), a value 2–4 fold
higher than reference values (10.4% ± 1.8) (Maier-Redelsperger et al.,Table 1
Patient characteristics.
SCA Control P
n = 54 n = 17
Age, days (median, range) 144 (81–196) 128 (68–621) 0.84
Haemoglobin, g/dL (median, range) 9.1 (6.5–12) 11 (7.2–12.6) b0.0001
Reticulocytes, % (median, range) 2.9 (0.5–10) 2 (0.5–4.2) 0.041994; Arceci IMH and Smith, 2006), and statistically increased when
compared to non-SCA infants (5.7% ± 3.6, P b 0.0001).
Median Hb level in SCA infants was 9.1 g/dL (6.5–12), a value signif-
icantly decreased in comparison with non-SCA infants (11 g/dL, 7.2–
12.6, P b 0.001) whilst median reticulocyte percentage was increased
in SCA infants (2.9%, 0.5–10 vs 2%, 0.5–4.2, P= 0.04).
3.2. Flow Cytometry Analysis of SCA Reticulocytes Demonstrates Increased
Expression of Erythroid Adhesion Markers
Reticulocytes from SCA infants displayed an overall statistically in-
creased expression of the following surface markers: CD239 (Lu/BCAM),
CD242 (ICAM-4/LW), CD58 (LFA-3), CD47 (IAP), CD99 (MIC2), CD147
(Basigin) and CD44 (Fig. 1). Because we calculated a ratio of positive
reticulocytes on total reticulocytes, these ﬁndings are not related to the
globally increased percentage of reticulocytes in SCA infants. Conversely,
no signiﬁcant differences were found on mature RBCs between SCA and
non-SCA patients (data not shown).
3.3. Lu/BCAM, ICAM-4 and LFA-3 are Overexpressed on SCA Reticulocytes
To further characterise the reticulocyte population in terms of
surface molecule expression, we analysed the protein expression level
of the 9 surfacemarkers bymeasuring theirmean ﬂuorescence intensity
(MFI). Here, MFI was statistically increased concerning two erythroid
adhesion molecules involved in SCA pathophysiology, namely Lu/BCAM
and ICAM-4, and a poorly described molecule in RBC physiology: LFA-3
(Fig. 2).
4. Discussion
Translational research is limited in SCA very young infants either
because diagnosis is delayed or because, in case of neonatal diagnosis,
parental approval for clinical trials is extremely difﬁcult to obtain at a
very young age in the setting of such a severe disease. Here, we conﬁrm
in a larger cohort of SCA infants aged less than 6 months, the very early
onset of haemolytic anaemia contrasting with the slow decline of HbF.
These results, consistent with previous reports (Maier-Redelsperger
et al., 1994; Steinberg et al., 2014), illustrate the pitfall of considering
elevated HbF level as protective. Measuring global HbF level by HPLC
or enumerating F cells overlooks the content of HbF at a cellular level
because the number of F-cells with polymer-inhibiting concentrations
of HbF is a more important determinant than the concentration of HbF
in the hemolysate or the total number of F-cells. However, quantitative
methods for measuring the amount of HbF in each F-cell (HbF/F-cell)
and plotting the distribution of HbF among F-cells are not available
(Steinberg et al., 2014). Measuring HbF does not address therefore the
heterogeneous distribution of HbF within RBCs and hence subpopula-
tions of RBCs prone to polymerisation, sickling and haemolysis because
of their very low content in HbF. These numerically small subpopula-
tions may in fact play an important pathophysiological role.
Erythroid adhesion molecules play a role in normal red blood cell
(RBC) physiology during erythropoiesis and erythrophagocytosis.
Expression level, clustering and activation state are critical for the adhe-
sive function. In normal conditions, circulating RBCs are not supposed
to adhere to any other cells nor to extracellular matrix components.
Most molecules therefore display a decreasing level of expression
throughout erythropoiesis. Our data demonstrates that between 3 and
5 months of age, reticulocytes characterised by markers that are other-
wise lost or decreased upon maturation, are found in the circulation. At
this same time point, mature RBCs display no signiﬁcant differences
compared to non-SCA, consistent with our hypothesis that their release
occurred shortly after birth at a time when no dyserythropoiesis is
expected to occur, as the HbF switch has not begun. This time frame,
therefore, allows a snapshot of the ﬁrst pathological changes occurring
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Fig. 1. Percentage of positive reticulocytes/total reticulocytes expressing CD239, CD242, CD58, CD47, CD99, CD147, CD44, CD36 and CD49d. Medians (line is at median with interquartile
range) were compared using Mann–Whitney test. ****: P b 0.0001, **: P b 0.01.
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reticulocytes.
Cytometric analysis of SCA RBCs indeed evidenced reticulocytes
overexpressing the erythroid adhesion molecules: Lu/BCAM, ICAM-4
and LFA-3, whilst no difference was evidenced on mature red cells.
Overexpression of Lu/BCAM and ICAM-4 has been demonstrated in
SCA (El Nemer et al., 1998; Parsons et al., 1999) and, importantly, func-
tional activation by phosphorylation (Gauthier et al., 2005) results in in-
creased RBC adhesion to vascular endothelium and resistance to high
shear-stress forces, thereby contributing to VOC genesis (Kaul et al.,
2006). Lu/BCAM is the carrier of the Lutheran and the BCAM antigens
and the unique erythroid receptor for lamininα5 chain, amajor compo-
nent of the sub endothelial extracellular matrix. It is expressed both on
erythroid and endothelial cells and is a receptor for α4β1 integrin
expressed on sickle reticulocytes and leukocytes (El Nemer et al.,
2007; Bartolucci et al., 2010).
ICAM-4 carries the antigens of the Landsteiner–Wiener (LW) blood
group system and is a ligand for a large repertoire of integrins including
αVβ3 present on endothelial cells. ICAM-4 undergoes phosphorylation
on serine along the PKA-dependent pathway. In addition to its adhesive
interaction with endothelial cells, ICAM-4 was shown to play a critical
role in vaso-occlusion in murine models through its interaction with
αVβ3 (Delahunty et al., 2006). Conversely, no data is available on the
role of LFA-3 in erythroid cells, but growing evidence points to LFA-3
as a novel functional marker involved in regulating the self-renewal of
tumour-initiating cells in colorectal cancer (Xu et al., 2014). Interesting-
ly, LFA-3 was found on the surface of exosomes released by rat reticulo-
cytes pointing out a mechanism through which it is down regulated
during terminal erythroid maturation (Vidal, 2010).
Known adhesion markers previously identiﬁed on SCA reticulocytes
i.e., CD36 and CD49d (α4β1/Very Late Antigen-4) (Swerlick et al., 1993;Joneckis et al., 1993) were not signiﬁcantly increased in our SCA infant
cohort (Fig. 1). This discrepancy may be explained by the overall
relatively low percentage of reticulocytes, as opposed to adults, and is
consistent with the ﬁndings of Odièvre et al. in SCA children (Odievre
et al., 2008).
Recent publications have pointed to the signiﬁcance of an elevat-
ed reticulocyte count in association with disease severity (Meier
et al., 2013, 2014). In this study we conﬁrm the very early onset of
reticulocytosis in SCA infants and demonstrate the presence of circu-
lating stress reticulocytes with a speciﬁc adhesion molecule proﬁle,
overexpressing the adhesion molecules Lu/BCAM, ICAM-4 and LFA-
3. This numerically small subpopulation of reticulocytes expressing
Lu/BCAM, ICAM-4 and LFA-3 could play a role in early infancy nota-
bly in splenic injury as these cells would be prone to splenic trapping
in the open circulation of the ﬁltering beds, through adhesion to
laminin and/or the spleen-speciﬁc endothelial cells of the venous
sinus (Brousse et al., 2014). Ongoing longitudinal analysis will conﬁrm
if this idiosyncratic erythroid adhesion molecule proﬁle in infants
indeed correlates with increased haemolysis and adhesion, functional
activation and disease severity.
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